Gene Therapy for WHIM Syndrome

This trial tests a groundbreaking gene therapy for individuals with WHIM syndrome, a rare immune disorder that causes serious infections. The treatment collects a person's stem cells, edits the faulty gene, and returns the modified cells, potentially curing the disorder. Eligible participants must have WHIM syndrome confirmed by a specific gene mutation and have experienced related symptoms, such as frequent infections. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Studies have shown that specially edited blood stem cells could safely treat WHIM syndrome. Research indicates that gene editing tools, such as CRISPR/Cas9, can deactivate the gene causing the disease in these cells. This method aims to correct the genetic issue behind WHIM syndrome, allowing the edited cells to grow and develop normally over time.

Unlike the standard treatments for WHIM Syndrome, such as antibiotics and granulocyte colony-stimulating factors (G-CSF), which primarily manage symptoms, this gene therapy uses base-edited hematopoietic stem and progenitor cells (HSPCs) to address the root cause of the condition. Researchers are excited because this therapy could potentially provide a one-time, long-lasting solution by correcting the genetic mutation responsible for WHIM Syndrome. This innovative approach could lead to fewer infections and improved immune function, offering hope for a more effective and sustainable treatment option.

Research has shown that specially edited stem cells might help treat WHIM syndrome. This gene therapy corrects the faulty CXCR4 gene responsible for the condition. Studies have found that this approach can reduce issues such as frequent infections and warts. In similar conditions, like sickle cell disease, this method has proven effective and reliable. This suggests that the treatment could lead to lasting improvements for people with WHIM syndrome. Participants in this trial will receive a one-time infusion of base-edited autologous hematopoietic stem and progenitor cells after myeloid conditioning with busulfan.¹³⁴⁶⁷